CREATING PARADIGM-SHIFTING SOLUTIONS IN DERMATOLOGY
Drug development in dermatology has concentrated on addressing a finite number of skin diseases. This has created a void in innovation where numerous common skin conditions continue to represent pervasive treatment challenges. Veradermics aims to create a paradigm shift in medical dermatology by developing innovative therapeutics that target real-world patient and physician problems for highly prevalent and bothersome skin conditions.
The company has curated a differentiated pipeline of novel therapeutics with potential first-in-class market opportunities. Veradermics has two assets, VDPHL and VDMN, in clinical trials. Learn more about the company's pipeline.